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Abstract
Background Insulin and multiple other autoantigens have been implicated
in the pathogenesis of autoimmune type 1 diabetes, but the origin of
immunological self-reactivity speciﬁcally oriented against insulin-secreting
islet b-cells remains obscure. The primary objective of the present study was
to investigate the hypothesis that a defect in thymic central T-cell self-
tolerance of the insulin hormone family could contribute to the pathophy-
siology of type 1 diabetes. This hypothesis was investigated in a classic animal
model of type 1 diabetes, the Bio-Breeding (BB) rat.
Methods The expression of the mammalian insulin-related genes (Ins, Igf1
and Igf2) was analysed in the thymus of inbred Wistar Furth rats (WF),
diabetes-resistant BB (BBDR) and diabetes-prone BB (BBDP) rats.
Results RT-PCR analyses of total RNA from WF, BBDP and BBDR thymi
revealed that Igf1 and Ins mRNAs are present in 15/15 thymi from 2-day-old,
5-day-old and 5-week-old WF, BBDR and BBDP rats. In contrast, a complete
absence of Igf2 mRNA was observed in more than 80% of BBDP thymi. The
absence of detectable Igf2 transcripts in the thymus of BBDP rats is tissue-
speciﬁc, since Igf2 mRNAs were detected in all BBDP brains and livers
examined. Using a speciﬁc immunoradiometric assay, the concentration of
thymic IGF-2 protein was signiﬁcantly lower in BBDP than in BBDR rats
(p<0.01).
Conclusions The present study suggests an association between the
emergence of autoimmune diabetes and a defect in Igf2 expression in the
thymus of BBDP rats. This tissue-speciﬁc defect in gene expression could
contribute both to the lymphopenia of these rats (by impaired T-cell
development) and the absence of central T-cell self-tolerance of the insulin
hormone family (by defective negative selection of self-reactive T-cells).
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Introduction
Type 1 diabetes is an autoimmune disease speciﬁcally directed against
insulin-secreting islet b-cells and several autoantigen targets have been
identiﬁed. In this cohort of autoantigens, insulin is the most speciﬁc
autoantigen of the islet b-cell. Insulin has been shown to play an important
role in the development of type 1 diabetes both in humans and in animal
models of type 1 diabetes [1–4]. Though the autoimmune nature of type 1
diabetes is well established, animal experiments and human clinical studies
have failed to determine the speciﬁc origin of the immunological
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self-reactivity against insulin-secreting islet b-cells. It has
been hypothesized, however, that speciﬁc self-reactivity
of the immune system may develop from a defect in the
thymic establishment of central self-tolerance [5–7].
After migrating from primary hematopoietic sites (fetal
yolk sac, fetal liver, and then bone marrow) into the
thymus, lymphoid stem cells are induced by thymic
signals to undergo a program of proliferation, gene
rearrangement and differentiation. These speciﬁc thymic
events result in the production of a large number
of immature double-positive CD4+CD8+ thymocytes
expressing a diverse repertoire of T-cell antigen receptor
(TCR) combinations. This repertoire is submitted to
stringent selection so that T-cells that recognize self-
antigens in the context of major histocompatibility
complexes (MHC) are induced to die by neglect or
by negative selection [8]. This efﬁcient deletion of
self-reactive T lymphocytes is responsible for the central
self-tolerance of the immune system. The tolerogenic
function of the thymus is mediated by the different cellular
components of the thymic parenchyme: epithelial/
nurse cells (TEC/TNC), macrophages, and dendritic
cells [9,10]. Central T-cell tolerance of neuroendocrine
functions has been proposed to be mediated by the
intrathymic expression of one dominant member of
neuroendocrine families [5,7].
Insulin-like growth factor 2 (IGF-2) is the dominant
polypeptide of the insulin family synthesized by TEC/TNC
in the human, rat and mouse thymus. Immunoreactive
(IR) IGF-1 is also detected in the thymus, but
IGF-1 distribution is restricted to stromal cells with a
macrophage-like morphology and distribution [11–15].
Using fetal thymic organ cultures, we demonstrated that
intrathymic IGF-mediated signaling plays an active role in
T-cell proliferation and differentiation during fetal
development [15]. Insulin gene (Ins) expression has
also been described in fetal and postnatal thymi from
humans, rats and mice [16–20]. The primary objective of
the present study was to explore whether a defect in the
thymic expression of a member of the insulin family could
be associated with the predisposition for autoimmune
diabetes. This was investigated using a classical animal
model for type 1 diabetes, the Bio-Breeding (BB) rat. BB
rats are susceptible to an autoimmune diabetes syndrome
that shares many characteristics with human type 1
diabetes [21].
Materials and methods
Animals and tissue isolation
Thymus, brain and liver of inbred Wistar-Furth (WF) rats,
diabetes-resistant (BBDR) and diabetes-prone (BBDP) BB
rats (2 days to 5 weeks of age) were taken from animals
obtained from the BB rat colony maintained at the
University of Massachusetts Medical School, Worcester,
MA. The animals in this colony have been inbred for more
than 50 generations and are housed in viral antibody free
(VAF) conditions. The overall incidence of diabetes in the
BBDP strain of BB rats is 86% between 56 and 120 days of
age and 0% in the BBDR strain. The experimental
procedures were carried out in accordance with the
Ethical Committee on Animal Experimentation at the
University of Lie`ge and the Institutional Animal Care
and Use Committee (IACUC) at the University of
Massachusetts Medical School.
RNA isolation and RT-PCR analyses
Tripure (Roche Diagnostics, Basel, Switzerland) was
added to tissue fragments, and RNA was extracted
according to the manufacturer’s instructions. Samples
were treated with RNase-free DNase I (Roche Diagnos-
tics) to remove potentially contaminating DNA. Each time
point was repeated three times.
Reverse transcription (RT) was performed using 3 mg
total RNA in the presence of 1 mM dNTP (Amersham
Pharmacia Biotech, Uppsala, Sweden), 50 mM Tris-HCl
pH 8.3, 75 mM KCl, 5 mM MgCl2, 30 IU avian reverse
transcriptase (Promega, Madison, WI, USA) and 500 nM
random hexamer primers (Amersham Pharmacia Biotech)
in a ﬁnal volume of 25 ml. Samples were incubated at
70uC for 10 min and 1 h at 42uC.
The PCR reaction was carried out in a ﬁnal volume of
50 ml using the equivalent of 600 ng total RNA (5 ml of the
RT reaction). The RNA was ampliﬁed in the presence of
10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2,
200 mM each of dATP, dCTP, dGTP, dTTP, 1.5 U TaKaRa
TaqTM DNA polymerase (all reagents from Takara Shuzo
Co. Ltd, Shiga, Japan) and 0.5 mM of each primer (Life
Technologies, Merelbeke, Belgium). The newly synthe-
sized cDNAs were denatured at 94uC for 3 min and
ampliﬁed by 30 PCR cycles at 94uC for 90 s, annealed for
90 s at the indicated temperature (55uC for IGF-1, 54uC
for IGF-2, 57uC for insulin and 54uC for actin), 72uC for
90 s, followed by 72uC for 10 min. The sequences of
oligonucleotide primers were as follows: Igf1 (upstream:
ATCTCTTCTACCTGGCAGTC, downstream: TACATCTC
CAGCCTCCTCAG); Igf2 (upstream: CACGCTTCAGTTTGT
CTGTT, downstream: CGGGGTCTTTGGGTGGTAAC); Ins
(upstream: ATGGC CCTGTGGATGCGCTTC, downstream:
GTTGCAGTAGTTCTCCAGTTG; these primers amplify
transcripts from both Ins1 and Ins2 genes) [22]; b actin
(upstream: GATGGTGGGTATGGGTCAGAAGGA, down-
stream: GCTCATTGCCGATAG TGATGACCT) [23]. To
exclude the possibility of amplifying genomic DNA,
primers were chosen in different exons of IGF genes.
Control PCRs have also been performed in the absence of
RT. PCR products were fractionated by electrophoresis on
1% agarose gel. The identity of the RT-PCR-products
ampliﬁed with Igf1, Igf2 and Ins primers was conﬁrmed by
Southern blotting.
Immunoradiometric assay of thymic
IGF-1 and IGF-2
The procedure used a two-site immunoradiometric assay
(IRMA) principle described by Miles et al. [24]. The
DSL-9100 ACTIVETM IGF-1 and IGF-2 IRMA (Diagnostic
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Systems Laboratories, Inc., Webstar, TX, USA), included a
simple extraction step in which IGF-1 and IGF-2 were
separated from their binding proteins. Thymic proteins
puriﬁed from 15 BBDR and 15 BBDP samples after RNA
isolation with tripure reagent were collected individually,
neutralized and submitted to the assay procedure. The
IRMA was performed in anti-IGF-1 or anti-IGF-2-coated
tubes. Aliquots (50 ml) of the reconstituted standard,
control and extracted proteins were incubated for 3 h at
room temperature on a shaker set at 180 rpm, then the
pellets were washed three times with 2 ml deionized
water. Tubes were incubated for 1 h at room temperature
with 100 ml anti-IGF-1 or anti-IGF-2 labeled antibodies,
decanted, washed three times, and bound radioactivity
was quantiﬁed using a gamma counter.
Statistical methods
Values obtained from multiple experiments are reported
as meantSEM. Signiﬁcance levels were determined by
Mann-Whitney U-test.
Results
Expression of Ins and Igfs in WF and
BB rat thymi
RT-PCR analyses of total RNA from BBDP and BBDR rat
thymi revealed that Igf1 and InsmRNAs are present in 15/
15 thymi from 5-day-old BBDR and BBDP (Figures 1 and
2). In contrast, no detectable Igf2 mRNA is observed in
most of the BBDP thymi (11/15). Since Igf2 mRNA in
rodents is known to decline after birth, we investigated
whether an earlier decrease in Igf2 mRNA expression
leads to the observed defect of Igf2 in BBDP rat thymi.
Igf2 transcripts were identiﬁed in the thymus of 10/10
5-week-old and 2-day-old BBDR and WF thymi, but Igf2
mRNAs were not detectable in more than 80% of the
thymi of 5-week-old and 2-day-old BBDP rats (Figures 3
and 4). The absence of detectable Igf2 transcripts in the
thymus of BBDP rats is tissue-speciﬁc, since Igf2 mRNAs
were readily detected in the brain and liver of these
animals (data not shown). Ampliﬁcation of b actin cDNA
(600 bp) was used as an internal standard (Figures 1–4).
Southern blotting was used to conﬁrm that the RT-PCR
products observed at the predicted sizes on the gels were
in fact the cDNAs of Ins, Igf1 and Igf2 (data not shown).
Characterization of IR IGF-1 and IGF-2
in BB rat thymus
Immunoreactive (IR) IGF-1 and IGF-2 in thymi of BBDP
and BBDR rats are shown in Figure 5. A marked
difference in the concentration of thymic IR IGF-2
concentrations was observed between the two groups
of rats (BBDP 11.2t0.91 ng/mg protein vs BBDR
30.7t4.17 ng/mg protein; meantSEM of 15 thymic
extracts). As assessed by Mann-Whitney U-test, this
difference was highly signiﬁcant (p<0.01) (Figure 5).
There was no signiﬁcant difference in IR IGF-1 concen-
trations in BBDP (12.1t0.21 ng/mg protein) and BBDR
(11.3t0.47 ng/mg protein) thymi.
Discussion
Autoimmune type 1 diabetes in humans and animal
models results from the destruction of insulin-secreting
islet b-cells by self-reactive T-cells [25]. The mechanisms
leading to the generation of these self-reactive T-cells are
still unknown. Among a number of identiﬁed islet b-cell
Figure 1. Ampliﬁcation of Igf1, Igf2, Ins and b actin mRNAs from 5-day-old diabetes-resistant (BBDR) rat thymi by RT-PCR. RT-
PCR products were separated by agarose gel electrophoresis and visualized with ethidium bromide. The predicted sizes for the
ampliﬁcation bands using primers speciﬁc for Igf1, Igf2 and Ins were 213, 378 and 322 bp, respectively. M1, 100 bp markers;
C, brain or pancreas as positive controls; H2O, negative control (no RNA). Ampliﬁcation of b actin cDNA (600 bp) was used as
an internal standard
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autoantigens, insulin is considered to be a critical target
and the most speciﬁc autoantigen of b-cells [2–4]. Insulin
as an immune target has been associated with the
development of autoimmune diabetes in humans and
NOD mice [1–4], though its role as an autoantigen in the
BB rat remains to be clariﬁed. Based on the data
implicating autoreactivity to insulin in the pathogenesis
of type 1 diabetes, both ourselves and others have
suggested that intrathymic expression of INS and IGF
could induce the central T-cell tolerance of the insulin
family [11,16–18,20].
Previously, defects in the cytoarchitecture of thymic
epithelium have been observed in BB rats and were
proposed to contribute both to the impairment of T-cell
differentiation and in the susceptibility to autoimmune
diabetes of these animals [26]. The present study shows a
defect of Igf2 expression in the thymus of more than 80%
of BBDP rats, while Igf1 and Ins are expressed in the thymi
of the three strains analyzed (BBDR, BBDP and WF). This
defect is tissue-speciﬁc, since BBDP rat brains and livers
express readily detectable Igf2 mRNA. There is a
concordance in the proportion of thymi that have defects
in Igf2 expression and the incidence rate of diabetes in
BBDP rats (86%). Since thymic IGF-mediated signaling
plays an active role in the early steps of T cell-
differentiation [15], the defect of thymic Igf2 expression
could also contribute with genetic factors (like lyp) to the
lymphopenia of these animals [27,28]. It will be of
interest to investigate whether the thymic Igf2 defect
contributes to the lack of regulatory RT6+ T-cells in BBDP
rats.
The molecular mechanisms responsible for the defect of
Igf2 expression in the thymus of BBDP rats remain to be
determined. Rat Igf2 contains six exons, is transcribed
from three distinct promoters (P1, P2 and P3), and is
expressed in a tissue-speciﬁc and developmentally
regulated manner [29–32]. In the rat fetus, Igf1 and
Igf2 are expressed in different tissues with a marked
predominance of Igf2 [33–35]. During the ﬁrst 3 weeks of
postnatal life, Igf2 transcripts gradually decline to very
low levels except in organs such as the brain, spinal cord,
striated muscle and thymus. Within these organs, Igf2
transcripts and IGF-2 protein are also detected
at adulthood [11,33,34,36,37]. In the present study,
Figure 3. Ampliﬁcation of Igf1, Igf2, Ins and b actin mRNAs from 2-day-old BBDP, BBDR and WF rat thymi by RT-PCR. RT-PCR
products were separated by agarose gel electrophoresis and visualized with ethidium bromide. M1, 100 bp markers; C, brain
or pancreas as positive controls; H2O, negative control (no RNA). Ampliﬁcation of b actin cDNA (600 bp) was used as an internal
standard
Figure 2. Ampliﬁcation of Igf1, Igf2, Ins and b actin mRNAs from 5-day-old diabetes-prone (BBDP) rats thymi by RT-PCR. RT-
PCR products were separated by agarose gel electrophoresis and visualized with ethidium bromide. M1, 100 bp markers; C,
brain or pancreas as positive controls; H2O, negative control (no RNA). Ampliﬁcation of b actin cDNA (600 bp) was used as an
internal standard
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Igf2 transcripts and IGF-2 proteins were present both in
adult and neonatal thymi from BBDR and WF rats.
Thymic Igf2 expression in BB rats is also under the control
of promoters P2 and P3 (data not shown). Since Igf2
transcripts are detected in brain and liver of BBDP rats, a
tissue-speciﬁc mechanism may be hypothesized to explain
the defect of Igf2 expression in the thymus of BBDP rats.
A balance of positive and negative inﬂuences between
different genes determines the susceptibility of BB rats to
autoimmune diabetes. The main diabetes susceptibility
locus in humans, mice and rats is the MHC class II gene. In
the BB rat, this susceptibility locus is the RT1u haplotype
on chromosome 20 (iddm2) [38]. A second non-MHC
locus strongly associated with diabetes susceptibility
present on chromosome 4 has been termed iddm4 [39].
The homozygous presence of the lymphopenia gene (lyp)
on chromosome 4 (iddm1) appears to remove regulatory
T-cells, thus permitting the susceptibility for diabetes
determined by iddm2 and iddm4 to be expressed [39,40].
In the absence of regulation due to the homozygous
presence of lyp, T-cell-mediated b-cell destruction and
overt hyperglycemia ensues. With regard to diabetes
resistance, a locus close to Igf2 has been described
recently [41].
The present study suggests an association between the
defect of Igf2 expression in the thymus and the emergence
of autoimmune diabetes in BBDP rats, but the extrapo-
lation of these ﬁndings to type 1 diabetes in humans is
premature. In humans, the IDDM2 type 1 diabetes
susceptibility locus maps to a variable number of
tandem repeat (VNTR) minisatellite upstream of INS
[42]. Protective VNTR class III alleles (140 to >200
repeats) are associated with higher levels of INS mRNA
levels in human thymus [17,18]. No signiﬁcant difference
in human thymic or pancreatic IGF2 mRNA levels can be
observed in association with the protective class of VNTR
alleles [43]. However, VNTR also has effects on IGF2
expression since, in placenta at term and HepG2
hepatoma cell line, higher IGF2 mRNA levels are
associated with shorter VNTR class I alleles than longer
VNTR class III alleles [44]. From these data, it clearly
appears that the mechanisms controlling the intrathymic
expression of insulin and insulin-related genes are
deserving of further investigation. Additional studies
are also required to distinguish the type of the immune
response (immunogenic or tolerogenic) elicited by oral
and parenteral administration of insulin and IGFs to pre-
diabetic and new-onset diabetic individuals. Preliminary
reports suggest that oral insulin is unable to promote
immunological tolerance to the residual b-cells in overtly
diabetic type 1 individuals [45,46]. However, the out-
come of the oral insulin arm of the diabetes prevention
trial in the DPT study in the United States has not yet been
reported. The available data suggest, however, that
investigation into alternative approaches to insulin for
immunomodulatory intervention in pre-diabetic and
new-onset diabetic individuals must continue.
Figure 5. IR IGF-1 and IGF-2 in thymi of BBDP and BBDR rats. Proteins of 15 individual thymi from BBDR and BBDP rats were
extracted and IR IGF-1 and IGF-2 were quantiﬁed with speciﬁc IRMAs (**p<0.01)
Figure 4. Ampliﬁcation of Igf1, Igf2, Ins and b actin mRNAs from 5-week-old BBDP, BBDR and WF rat thymi by RT-PCR. RT-
PCR products were separated by agarose gel electrophoresis and visualized with ethidium bromide. M1, 100 bp markers; C,
brain or pancreas as positive control; H2O, negative control (no RNA). Ampliﬁcation of b actin cDNA (600 bp) was used as an
internal standard
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